APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody-drug Conjugate for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antibody-drug Conjugate for Cancer Market Analysis and Forecast 2026-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchAntibody-drug Conjugate for Cancer Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody-drug Conjugate for Cancer Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Antibody-drug Conjugate for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody-drug Conjugate for Cancer Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody-drug Conjugate for Cancer Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Antibody-drug Conjugate for Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Antibody-drug Conjugate for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antibody-drug Conjugate for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antibody-drug Conjugate for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antibody-drug Conjugate for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Antibody-drug Conjugate for Cancer include Gilead Sciences, Innate Pharma, Rakuten Medical, Seagen, AstraZeneca, GSK, Pfizer, Roche and Takeda, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Antibody-drug Conjugate for Cancer, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antibody-drug Conjugate for Cancer, also provides the revenue of main regions and countries. Of the upcoming market potential for Antibody-drug Conjugate for Cancer, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibody-drug Conjugate for Cancer revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antibody-drug Conjugate for Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Antibody-drug Conjugate for Cancer revenue, projected growth trends, production technology, application and end-user industry.

Antibody-drug Conjugate for Cancer Segment by Company

Gilead Sciences

Innate Pharma

Rakuten Medical

Seagen

AstraZeneca

GSK

Pfizer

Roche

Takeda

Antibody-drug Conjugate for Cancer Segment by Type

Hematological Malignancies Drugs

Solid Tumor Drugs

Antibody-drug Conjugate for Cancer Segment by Application

Hospital

Pharmacy

Other

Antibody-drug Conjugate for Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugate for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugate for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugate for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Antibody-drug Conjugate for Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Antibody-drug Conjugate for Cancer company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody-drug Conjugate for Cancer revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Hematological Malignancies Drugs Major Player Table 3. Solid Tumor Drugs Major Player Table 4. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Pharmacy Major Player Table 7. Other Major Player Table 8. Antibody-drug Conjugate for Cancer Industry Trends Table 9. Antibody-drug Conjugate for Cancer Industry Drivers Table 10. Antibody-drug Conjugate for Cancer Industry Opportunities and Challenges Table 11. Antibody-drug Conjugate for Cancer Industry Restraints Table 12. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Antibody-drug Conjugate for Cancer Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Antibody-drug Conjugate for Cancer Market Share by Region (2021-2026) Table 15. Global Antibody-drug Conjugate for Cancer Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Antibody-drug Conjugate for Cancer Market Share by Region (2027-2032) Table 17. Global Antibody-drug Conjugate for Cancer Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Players (2021-2026) Table 19. Global Antibody-drug Conjugate for Cancer Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Antibody-drug Conjugate for Cancer Key Players Headquarters & Area Served Table 21. Global Antibody-drug Conjugate for Cancer Players, Product Type & Application Table 22. Global Antibody-drug Conjugate for Cancer Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Antibody-drug Conjugate for Cancer by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Antibody-drug Conjugate for Cancer Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2021-2026) Table 29. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2027-2032) Table 30. Global Antibody-drug Conjugate for Cancer Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2021-2026) Table 34. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2027-2032) Table 35. Gilead Sciences Company Information Table 36. Gilead Sciences Business Overview Table 37. Gilead Sciences Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Gilead Sciences Antibody-drug Conjugate for Cancer Product Portfolio Table 39. Gilead Sciences Recent Development Table 40. Innate Pharma Company Information Table 41. Innate Pharma Business Overview Table 42. Innate Pharma Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Innate Pharma Antibody-drug Conjugate for Cancer Product Portfolio Table 44. Innate Pharma Recent Development Table 45. Rakuten Medical Company Information Table 46. Rakuten Medical Business Overview Table 47. Rakuten Medical Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Rakuten Medical Antibody-drug Conjugate for Cancer Product Portfolio Table 49. Rakuten Medical Recent Development Table 50. Seagen Company Information Table 51. Seagen Business Overview Table 52. Seagen Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Seagen Antibody-drug Conjugate for Cancer Product Portfolio Table 54. Seagen Recent Development Table 55. AstraZeneca Company Information Table 56. AstraZeneca Business Overview Table 57. AstraZeneca Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. AstraZeneca Antibody-drug Conjugate for Cancer Product Portfolio Table 59. AstraZeneca Recent Development Table 60. GSK Company Information Table 61. GSK Business Overview Table 62. GSK Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. GSK Antibody-drug Conjugate for Cancer Product Portfolio Table 64. GSK Recent Development Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Pfizer Antibody-drug Conjugate for Cancer Product Portfolio Table 69. Pfizer Recent Development Table 70. Roche Company Information Table 71. Roche Business Overview Table 72. Roche Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Roche Antibody-drug Conjugate for Cancer Product Portfolio Table 74. Roche Recent Development Table 75. Takeda Company Information Table 76. Takeda Business Overview Table 77. Takeda Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Takeda Antibody-drug Conjugate for Cancer Product Portfolio Table 79. Takeda Recent Development Table 80. North America Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 81. North America Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 82. North America Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 83. North America Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 84. North America Antibody-drug Conjugate for Cancer Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. North America Antibody-drug Conjugate for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Antibody-drug Conjugate for Cancer Revenue by Country (US$ Million) & (2027-2032) Table 87. Europe Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 88. Europe Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 89. Europe Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 90. Europe Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 91. Europe Antibody-drug Conjugate for Cancer Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. Europe Antibody-drug Conjugate for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 93. Europe Antibody-drug Conjugate for Cancer Revenue by Country (US$ Million) & (2027-2032) Table 94. China Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 95. China Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 96. China Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 97. China Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 99. Asia Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 100. Asia Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 101. Asia Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia Antibody-drug Conjugate for Cancer Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Asia Antibody-drug Conjugate for Cancer Revenue by Region (US$ Million) & (2021-2026) Table 104. Asia Antibody-drug Conjugate for Cancer Revenue by Region (US$ Million) & (2027-2032) Table 105. SAMEA Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 106. SAMEA Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 107. SAMEA Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 108. SAMEA Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 109. SAMEA Antibody-drug Conjugate for Cancer Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. SAMEA Antibody-drug Conjugate for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 111. SAMEA Antibody-drug Conjugate for Cancer Revenue by Country (US$ Million) & (2027-2032) Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Antibody-drug Conjugate for Cancer Image Figure 2. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody-drug Conjugate for Cancer Market Size Share 2021 VS 2025 VS 2032 Figure 4. Hematological Malignancies Drugs Image Figure 5. Solid Tumor Drugs Image Figure 6. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Antibody-drug Conjugate for Cancer Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global Antibody-drug Conjugate for Cancer Market Size (US$ Million) & (2021-2032) Figure 12. Global Antibody-drug Conjugate for Cancer Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Antibody-drug Conjugate for Cancer Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Antibody-drug Conjugate for Cancer Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Antibody-drug Conjugate for Cancer Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antibody-drug Conjugate for Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2021-2032) Figure 19. Global Antibody-drug Conjugate for Cancer Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2021-2032) Figure 22. North America Antibody-drug Conjugate for Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Antibody-drug Conjugate for Cancer Revenue Share by Type (2021-2032) Figure 24. North America Antibody-drug Conjugate for Cancer Revenue Share by Application (2021-2032) Figure 25. North America Antibody-drug Conjugate for Cancer Revenue Share by Country (2021-2032) Figure 26. United States Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Antibody-drug Conjugate for Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Antibody-drug Conjugate for Cancer Revenue Share by Type (2021-2032) Figure 31. Europe Antibody-drug Conjugate for Cancer Revenue Share by Application (2021-2032) Figure 32. Europe Antibody-drug Conjugate for Cancer Revenue Share by Country (2021-2032) Figure 33. Germany Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Antibody-drug Conjugate for Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Antibody-drug Conjugate for Cancer Revenue Share by Type (2021-2032) Figure 43. China Antibody-drug Conjugate for Cancer Revenue Share by Application (2021-2032) Figure 44. Asia Antibody-drug Conjugate for Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Antibody-drug Conjugate for Cancer Revenue Share by Type (2021-2032) Figure 46. Asia Antibody-drug Conjugate for Cancer Revenue Share by Application (2021-2032) Figure 47. Asia Antibody-drug Conjugate for Cancer Revenue Share by Region (2021-2032) Figure 48. Japan Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Antibody-drug Conjugate for Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Antibody-drug Conjugate for Cancer Revenue Share by Type (2021-2032) Figure 56. SAMEA Antibody-drug Conjugate for Cancer Revenue Share by Application (2021-2032) Figure 57. SAMEA Antibody-drug Conjugate for Cancer Revenue Share by Country (2021-2032) Figure 58. Brazil Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Antibody-drug Conjugate for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Hematological Malignancies Drugs
  • Solid Tumor Drugs
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Gilead Sciences
  • Innate Pharma
  • Rakuten Medical
  • Seagen
  • AstraZeneca
  • GSK
  • Pfizer
  • Roche
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antibody-drug Conjugate for Cancer Market by Type
  3. 1.2.1 Global Antibody-drug Conjugate for Cancer Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Hematological Malignancies Drugs
  5. 1.2.3 Solid Tumor Drugs
  6. 1.3 Antibody-drug Conjugate for Cancer Market by Application
  7. 1.3.1 Global Antibody-drug Conjugate for Cancer Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Antibody-drug Conjugate for Cancer Market Dynamics
  1. 2.1 Antibody-drug Conjugate for Cancer Industry Trends
  2. 2.2 Antibody-drug Conjugate for Cancer Industry Drivers
  3. 2.3 Antibody-drug Conjugate for Cancer Industry Opportunities and Challenges
  4. 2.4 Antibody-drug Conjugate for Cancer Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Antibody-drug Conjugate for Cancer Market Perspective (2021-2032)
  2. 3.2 Global Antibody-drug Conjugate for Cancer Growth Trends by Region
  3. 3.2.1 Global Antibody-drug Conjugate for Cancer Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antibody-drug Conjugate for Cancer Market Size by Region (2021-2026)
  5. 3.2.3 Global Antibody-drug Conjugate for Cancer Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Antibody-drug Conjugate for Cancer Revenue by Players
  2. 4.1.1 Global Antibody-drug Conjugate for Cancer Revenue by Players (2021-2026)
  3. 4.1.2 Global Antibody-drug Conjugate for Cancer Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Antibody-drug Conjugate for Cancer Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antibody-drug Conjugate for Cancer Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Antibody-drug Conjugate for Cancer Key Players Headquarters & Area Served
  7. 4.4 Global Antibody-drug Conjugate for Cancer Players, Product Type & Application
  8. 4.5 Global Antibody-drug Conjugate for Cancer Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Antibody-drug Conjugate for Cancer Market CR5 and HHI
  11. 4.6.3 2025 Antibody-drug Conjugate for Cancer Tier 1, Tier 2, and Tier 3
5 Antibody-drug Conjugate for Cancer Market Size by Type
  1. 5.1 Global Antibody-drug Conjugate for Cancer Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Antibody-drug Conjugate for Cancer Revenue by Type (2021-2032)
  3. 5.3 Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2021-2032)
6 Antibody-drug Conjugate for Cancer Market Size by Application
  1. 6.1 Global Antibody-drug Conjugate for Cancer Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Antibody-drug Conjugate for Cancer Revenue by Application (2021-2032)
  3. 6.3 Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Gilead Sciences
  2. 7.1.1 Gilead Sciences Company Information
  3. 7.1.2 Gilead Sciences Business Overview
  4. 7.1.3 Gilead Sciences Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Gilead Sciences Antibody-drug Conjugate for Cancer Product Portfolio
  6. 7.1.5 Gilead Sciences Recent Developments
  7. 7.2 Innate Pharma
  8. 7.2.1 Innate Pharma Company Information
  9. 7.2.2 Innate Pharma Business Overview
  10. 7.2.3 Innate Pharma Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Innate Pharma Antibody-drug Conjugate for Cancer Product Portfolio
  12. 7.2.5 Innate Pharma Recent Developments
  13. 7.3 Rakuten Medical
  14. 7.3.1 Rakuten Medical Company Information
  15. 7.3.2 Rakuten Medical Business Overview
  16. 7.3.3 Rakuten Medical Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Rakuten Medical Antibody-drug Conjugate for Cancer Product Portfolio
  18. 7.3.5 Rakuten Medical Recent Developments
  19. 7.4 Seagen
  20. 7.4.1 Seagen Company Information
  21. 7.4.2 Seagen Business Overview
  22. 7.4.3 Seagen Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Seagen Antibody-drug Conjugate for Cancer Product Portfolio
  24. 7.4.5 Seagen Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Antibody-drug Conjugate for Cancer Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 GSK
  32. 7.6.1 GSK Company Information
  33. 7.6.2 GSK Business Overview
  34. 7.6.3 GSK Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GSK Antibody-drug Conjugate for Cancer Product Portfolio
  36. 7.6.5 GSK Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Antibody-drug Conjugate for Cancer Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Roche
  44. 7.8.1 Roche Company Information
  45. 7.8.2 Roche Business Overview
  46. 7.8.3 Roche Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Roche Antibody-drug Conjugate for Cancer Product Portfolio
  48. 7.8.5 Roche Recent Developments
  49. 7.9 Takeda
  50. 7.9.1 Takeda Company Information
  51. 7.9.2 Takeda Business Overview
  52. 7.9.3 Takeda Antibody-drug Conjugate for Cancer Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Takeda Antibody-drug Conjugate for Cancer Product Portfolio
  54. 7.9.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Antibody-drug Conjugate for Cancer Revenue (2021-2032)
  2. 8.2 North America Antibody-drug Conjugate for Cancer Revenue by Type (2021-2032)
  3. 8.2.1 North America Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026)
  4. 8.2.2 North America Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032)
  5. 8.3 North America Antibody-drug Conjugate for Cancer Revenue Share by Type (2021-2032)
  6. 8.4 North America Antibody-drug Conjugate for Cancer Revenue by Application (2021-2032)
  7. 8.4.1 North America Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026)
  8. 8.4.2 North America Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032)
  9. 8.5 North America Antibody-drug Conjugate for Cancer Revenue Share by Application (2021-2032)
  10. 8.6 North America Antibody-drug Conjugate for Cancer Revenue by Country
  11. 8.6.1 North America Antibody-drug Conjugate for Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Antibody-drug Conjugate for Cancer Revenue by Country (2021-2026)
  13. 8.6.3 North America Antibody-drug Conjugate for Cancer Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Antibody-drug Conjugate for Cancer Revenue (2021-2032)
  2. 9.2 Europe Antibody-drug Conjugate for Cancer Revenue by Type (2021-2032)
  3. 9.2.1 Europe Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026)
  4. 9.2.2 Europe Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032)
  5. 9.3 Europe Antibody-drug Conjugate for Cancer Revenue Share by Type (2021-2032)
  6. 9.4 Europe Antibody-drug Conjugate for Cancer Revenue by Application (2021-2032)
  7. 9.4.1 Europe Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026)
  8. 9.4.2 Europe Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032)
  9. 9.5 Europe Antibody-drug Conjugate for Cancer Revenue Share by Application (2021-2032)
  10. 9.6 Europe Antibody-drug Conjugate for Cancer Revenue by Country
  11. 9.6.1 Europe Antibody-drug Conjugate for Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Antibody-drug Conjugate for Cancer Revenue by Country (2021-2026)
  13. 9.6.3 Europe Antibody-drug Conjugate for Cancer Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Antibody-drug Conjugate for Cancer Revenue (2021-2032)
  2. 10.2 China Antibody-drug Conjugate for Cancer Revenue by Type (2021-2032)
  3. 10.2.1 China Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026)
  4. 10.2.2 China Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032)
  5. 10.3 China Antibody-drug Conjugate for Cancer Revenue Share by Type (2021-2032)
  6. 10.4 China Antibody-drug Conjugate for Cancer Revenue by Application (2021-2032)
  7. 10.4.1 China Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026)
  8. 10.4.2 China Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032)
  9. 10.5 China Antibody-drug Conjugate for Cancer Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antibody-drug Conjugate for Cancer Revenue (2021-2032)
  2. 11.2 Asia Antibody-drug Conjugate for Cancer Revenue by Type (2021-2032)
  3. 11.2.1 Asia Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026)
  4. 11.2.2 Asia Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032)
  5. 11.3 Asia Antibody-drug Conjugate for Cancer Revenue Share by Type (2021-2032)
  6. 11.4 Asia Antibody-drug Conjugate for Cancer Revenue by Application (2021-2032)
  7. 11.4.1 Asia Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026)
  8. 11.4.2 Asia Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032)
  9. 11.5 Asia Antibody-drug Conjugate for Cancer Revenue Share by Application (2021-2032)
  10. 11.6 Asia Antibody-drug Conjugate for Cancer Revenue by Country
  11. 11.6.1 Asia Antibody-drug Conjugate for Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Antibody-drug Conjugate for Cancer Revenue by Country (2021-2026)
  13. 11.6.3 Asia Antibody-drug Conjugate for Cancer Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antibody-drug Conjugate for Cancer Revenue (2021-2032)
  2. 12.2 SAMEA Antibody-drug Conjugate for Cancer Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Antibody-drug Conjugate for Cancer Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Antibody-drug Conjugate for Cancer Revenue by Type (2027-2032)
  5. 12.3 SAMEA Antibody-drug Conjugate for Cancer Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Antibody-drug Conjugate for Cancer Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Antibody-drug Conjugate for Cancer Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Antibody-drug Conjugate for Cancer Revenue by Application (2027-2032)
  9. 12.5 SAMEA Antibody-drug Conjugate for Cancer Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Antibody-drug Conjugate for Cancer Revenue by Country
  11. 12.6.1 SAMEA Antibody-drug Conjugate for Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Antibody-drug Conjugate for Cancer Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Antibody-drug Conjugate for Cancer Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst